PA8484301A1 - Formulaciones farmaceuticas de liberacion controlada - Google Patents

Formulaciones farmaceuticas de liberacion controlada

Info

Publication number
PA8484301A1
PA8484301A1 PA19998484301A PA8484301A PA8484301A1 PA 8484301 A1 PA8484301 A1 PA 8484301A1 PA 19998484301 A PA19998484301 A PA 19998484301A PA 8484301 A PA8484301 A PA 8484301A PA 8484301 A1 PA8484301 A1 PA 8484301A1
Authority
PA
Panama
Prior art keywords
pharmaceutical formulations
controlled liberation
liberation
controlled
formulations
Prior art date
Application number
PA19998484301A
Other languages
English (en)
Inventor
Elizabeth King
Ross James Macrae
Original Assignee
Warner Lambert Exp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8484301(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en
Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en
Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en
Application filed by Warner Lambert Exp Ltd filed Critical Warner Lambert Exp Ltd
Publication of PA8484301A1 publication Critical patent/PA8484301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION PROPORCIONA FORMULACIONES FARMACEUTICAS DE LIBERACION CONTROLADA PARA ADMINISTRACION ORAL QUE CONTIENEN UN INHIBIDOR GMPC PDE-5. LAS FORMULACIONES SON UTILES, ENTRE OTROS, EN EL TRATAMIENTO O PREVENCION DE LA DISFUNCION SEXUAL.
PA19998484301A 1998-10-23 1999-10-18 Formulaciones farmaceuticas de liberacion controlada PA8484301A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9823192.1A GB9823192D0 (en) 1998-10-23 1998-10-23 Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en) 1998-11-16 1998-11-16 Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en) 1998-11-27 1998-11-27 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
PA8484301A1 true PA8484301A1 (es) 2000-09-29

Family

ID=27269526

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998484301A PA8484301A1 (es) 1998-10-23 1999-10-18 Formulaciones farmaceuticas de liberacion controlada

Country Status (44)

Country Link
US (1) US6964780B1 (es)
EP (1) EP1123088B1 (es)
JP (1) JP2002528408A (es)
KR (1) KR20010075659A (es)
CN (1) CN1324233A (es)
AP (1) AP2001002125A0 (es)
AT (1) ATE340562T1 (es)
AU (1) AU756509B2 (es)
BG (1) BG65323B1 (es)
BR (1) BR9914718A (es)
CA (1) CA2348086C (es)
CO (1) CO5160262A1 (es)
CR (1) CR6326A (es)
CY (1) CY1106239T1 (es)
CZ (1) CZ20011427A3 (es)
DE (1) DE69933383T2 (es)
DK (1) DK1123088T3 (es)
DZ (1) DZ2923A1 (es)
EA (1) EA004068B1 (es)
EE (1) EE200100235A (es)
ES (1) ES2272082T3 (es)
GT (1) GT199900184A (es)
HK (1) HK1041818A1 (es)
HR (1) HRP20010285A2 (es)
HU (1) HUP0104318A3 (es)
ID (1) ID28232A (es)
IL (1) IL141764A (es)
IS (1) IS5865A (es)
MA (1) MA26700A1 (es)
MX (1) MXPA01004011A (es)
MY (1) MY130727A (es)
NO (1) NO20011933L (es)
NZ (1) NZ510275A (es)
OA (1) OA11664A (es)
PA (1) PA8484301A1 (es)
PE (1) PE20001286A1 (es)
PL (1) PL195789B1 (es)
PT (1) PT1123088E (es)
SK (1) SK286473B6 (es)
TR (1) TR200101103T2 (es)
TW (1) TW577756B (es)
UA (1) UA67802C2 (es)
UY (1) UY25765A1 (es)
WO (1) WO2000024383A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1049695E (pt) * 1997-11-12 2002-07-31 Bayer Ag Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
WO2000025752A1 (en) 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
BRPI0015284B8 (pt) 1999-10-29 2021-05-25 Euro Celtique S/A formulações de hidrocodona de liberação controlada
KR100610131B1 (ko) * 2000-09-06 2006-08-09 다나베 세이야꾸 가부시키가이샤 경구 투여용 제제
KR101045144B1 (ko) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US7927623B2 (en) 2001-02-15 2011-04-19 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
MXPA06013133A (es) 2004-05-11 2007-05-23 Emotional Brain Bv Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
CA2613617A1 (en) * 2005-06-27 2007-01-04 Daniel Drai Compositions and methods for enhancement of sexual function
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
BRPI0616633A2 (pt) * 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
AR062320A1 (es) 2006-08-14 2008-10-29 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas
CN104721168A (zh) 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放***及其制造方法
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
JP2010532319A (ja) * 2007-06-13 2010-10-07 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 聴覚障害の処置用のｐｄｅ阻害剤
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
WO2009098697A1 (en) * 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
WO2010067140A1 (es) * 2008-12-12 2010-06-17 Siegfried Rhein S.A. De C.V. Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
BR112013029199B1 (pt) 2011-05-13 2022-02-08 Eb Ip Hybritabs B.V. Dispositivo de distribuição de dois fármacos
US20140328911A1 (en) * 2011-07-22 2014-11-06 Pom Wonderful. Llc Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN113995727B (zh) * 2021-11-08 2023-04-07 山东鲁抗医药股份有限公司 一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) * 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
ATE195252T1 (de) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
WO1997048382A2 (en) * 1996-06-18 1997-12-24 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
HUP0002744A3 (en) * 1997-01-06 2001-01-29 Pfizer Rapidly releasing and taste-masking pharmaceutical dosage form
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
DE69916627T2 (de) * 1998-09-04 2005-07-28 Ortho-Mcneil Pharmaceutical, Inc. 5-heterozyklyl-pyrazolo[4,3-d]pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen

Also Published As

Publication number Publication date
NO20011933L (no) 2001-06-25
CZ20011427A3 (cs) 2001-10-17
GT199900184A (es) 2001-04-14
SK286473B6 (sk) 2008-11-06
CA2348086C (en) 2007-01-23
HRP20010285A2 (en) 2002-06-30
HK1041818A1 (zh) 2002-07-26
ID28232A (id) 2001-05-10
UY25765A1 (es) 2001-08-27
UA67802C2 (uk) 2004-07-15
DE69933383T2 (de) 2007-02-01
EA200100298A1 (ru) 2001-08-27
IL141764A (en) 2008-06-05
MXPA01004011A (es) 2003-03-10
CN1324233A (zh) 2001-11-28
PL195789B1 (pl) 2007-10-31
KR20010075659A (ko) 2001-08-09
WO2000024383A1 (en) 2000-05-04
NZ510275A (en) 2003-07-25
MA26700A1 (fr) 2004-12-20
CY1106239T1 (el) 2011-06-08
ES2272082T3 (es) 2007-04-16
BG65323B1 (bg) 2008-02-29
BR9914718A (pt) 2001-07-10
TR200101103T2 (tr) 2001-09-21
US6964780B1 (en) 2005-11-15
SK5192001A3 (en) 2002-09-10
PE20001286A1 (es) 2000-11-22
IL141764A0 (en) 2002-03-10
AU5878799A (en) 2000-05-15
OA11664A (en) 2005-01-07
HUP0104318A3 (en) 2003-12-29
JP2002528408A (ja) 2002-09-03
CA2348086A1 (en) 2000-05-04
DZ2923A1 (fr) 2004-03-01
NO20011933D0 (no) 2001-04-19
CO5160262A1 (es) 2002-05-30
DE69933383D1 (de) 2006-11-09
EP1123088B1 (en) 2006-09-27
ATE340562T1 (de) 2006-10-15
DK1123088T3 (da) 2007-01-02
AP2001002125A0 (en) 2001-04-04
EA004068B1 (ru) 2003-12-25
MY130727A (en) 2007-07-31
PT1123088E (pt) 2007-01-31
AU756509B2 (en) 2003-01-16
EE200100235A (et) 2002-08-15
TW577756B (en) 2004-03-01
PL347476A1 (en) 2002-04-08
IS5865A (is) 2001-02-27
BG105465A (bg) 2001-12-29
CR6326A (es) 2004-02-23
EP1123088A1 (en) 2001-08-16
HUP0104318A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
ES2183937T3 (es) Inhibidores de la adhesion celular.
CR9465A (es) Compuestos mejorados farmacocineticamente
ES2164842T3 (es) Procedimiento para la preparacion de composiciones de microcapsulas.
AR015946A1 (es) Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
PA8452701A1 (es) Agonistas de prostaglandinas
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
SV1998000029A (es) Compuestos de pirazina ref. pg3186
HN2000000166A (es) Composicion de ovulos intravaginales de clindamicina
UY27259A1 (es) Derivados de dihidro-benzo b 1, 4- diazepin-2ona como antagonistas i de mglur2
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
ES2189956T3 (es) Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.
ECSP034530A (es) Derivados de 6-metil-tramadol sustituido en o
PA8552301A1 (es) Metodo para el tratamiento de insomnio primario
AR019492A1 (es) COMPOSICIONES FARMACÉUTICAS DE LIBERACIoN CONTROLADA
HUP0400528A2 (hu) Neuropeptidáz Y inhibitor alkalmazása férfiak szexuális funkciózavarának kezelésére alkalmas gyógyszerkészítmény előállítására